Uitterlinden Andre G, Arp Pascal P, Paeper Bryan W, Charmley Patrick, Proll Sean, Rivadeneira Fernando, Fang Yue, van Meurs Joyce B J, Britschgi Theresa B, Latham John A, Schatzman Randall C, Pols Huibert A P, Brunkow Mary E
Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands.
Am J Hum Genet. 2004 Dec;75(6):1032-45. doi: 10.1086/426458. Epub 2004 Oct 26.
Osteoporosis has a strong genetic component, but the genes involved are poorly defined. We studied whether the sclerosteosis/van Buchem disease gene (SOST) is an osteoporosis-risk gene by examining its association with bone-mineral density (BMD). Mutations in SOST result in sclerosteosis, and alterations in the SOST gene expression may be causal in the closely related van Buchem disease. We used a set of eight polymorphisms from the SOST gene region to genotype 1,939 elderly men and women from a large population-based prospective-cohort study of Dutch whites. A 3-bp insertion (f=0.38) in the presumed SOST promoter region (SRP3) was associated with decreased BMD in women at the femoral neck (FN) (P=.05) and lumbar spine (LS) (P=.01), with evidence of an allele-dose effect in the oldest age group (P=.006). Similarly, a G variant (f=0.40) in the van Buchem deletion region (SRP9) was associated with increased BMD in men at the FN (P=.007) and LS (P=.02). In both cases, differences between extreme genotypes reached 0.2 SD. We observed no genotype effects on fracture risk, for the 234 osteoporotic fractures validated during 8.2 years of follow-up and for the 146 vertebral prevalent fractures analyzed. We did not find association between any of several frequent haplotypes across the SOST gene region and BMD. We did find evidence of additive effects of SRP3 with the COLIA1 Sp1 polymorphism but not with haplotypes of 3' polymorphisms in the vitamin-D receptor gene. The SOST-COLIA1 additive effect increased with age and reached 0.5 SD difference in BMD at LS in the oldest age group (P=.02). The molecular mechanism whereby these moderate SOST genotype effects are mediated remains to be elucidated, but it is likely to involve differences in regulation of SOST gene expression.
骨质疏松症有很强的遗传因素,但相关基因尚不明确。我们通过研究硬化性骨病/范布赫姆病基因(SOST)与骨密度(BMD)的关联,来探讨该基因是否为骨质疏松症风险基因。SOST基因突变会导致硬化性骨病,而SOST基因表达的改变可能是与之密切相关的范布赫姆病的病因。我们利用一组来自SOST基因区域的8个多态性位点,对1939名来自荷兰白人基于人群的前瞻性队列研究中的老年男性和女性进行基因分型。推测的SOST启动子区域(SRP3)中的一个3碱基插入(f = 0.38)与女性股骨颈(FN)(P = 0.05)和腰椎(LS)(P = 0.01)骨密度降低相关,在最年长年龄组中有等位基因剂量效应的证据(P = 0.006)。同样,范布赫姆缺失区域(SRP9)中的一个G变异(f = 0.40)与男性FN(P = 0.007)和LS(P = 0.02)骨密度增加相关。在这两种情况下,极端基因型之间的差异均达到0.2个标准差。在8.2年的随访期间确认的234例骨质疏松性骨折以及分析的146例椎体现患骨折中,我们未观察到基因型对骨折风险有影响。我们未发现SOST基因区域的几种常见单倍型中的任何一种与骨密度之间存在关联。我们确实发现SRP3与COLIA1 Sp1多态性存在加性效应,但与维生素D受体基因3'多态性的单倍型不存在加性效应。SOST - COLIA1加性效应随年龄增加,在最年长年龄组中LS的骨密度差异达到0.5个标准差(P = 0.02)。这些适度的SOST基因型效应所介导的分子机制仍有待阐明,但可能涉及SOST基因表达调控的差异。